HTBX has very low financial risk with no debt, sufficiently solvent to operate into Q1 2022 w/o dilutive financing.
Heat has strategically been posting updates regarding its vaccine progress and said it will begin manufacturing BY August(the key word is BY). That means any day in the following few weeks the PR of its completion and most likely the announcement of some sort of grant (I.e. OWS, which can’t be disclosed until finalized which can’t be done until proof of concept is complete/manufacturing can begin).
Either way, when this happens the company should be worth At least in the 250M range ($2.95/share).
This will happen within a day of the news dropping and it will then sustain above 1$ per share the following 10 days.
If you did your DD you’ll know they’re right on schedule.
Anyways in the following weeks it would trigger more attention from institutional funds and hopefully lead to an addition to the Russel 2000/3000 indices. That would in turn allow funds with stricter investment protocols to invest.
This would easily bring the value of the company to 400M (~$4.75/share)
This doesn’t even include the rapid diagnostic test, or any of the oncology pipeline, including a hopeful inclusion into phase 3 of HS-110 (small cell lung cancer drug) which has a 70B target market...
HTBX they are a great team and have potential to reach a 2B(~$23.5/share) valuation within 2 years if HS-110 can make it to market. This is because over 50% of phase 3 drugs make it to market, and some are even marketable during phase 3 which would make the stock fly in value on news of phase 3 inclusion/grant.
I can also only imagine if they succeed with their so called “super-vaccine” as well as their other drugs and diagnostic test kit for Covid.
Anyways, with the potential upside for HTBX implied risk adjusted return is ludicrous.
NVAX Covid vaccine 6 Billion Market close to $100.00 stock
INO Covid vaccine $24.00 Stock 3.7 Billion market cap
HTBX vaccine will last longer than NVAX & INO Vaccine probably two years or longer possible single shot cure. The chart and the technicals are in a sweet spot for a parabolic run.
HTBX $1.01 75 million market cap
Catalysts:
1.Well Tested diverse cancer Platform with a recent 15.2 million dollar grant for a phase 1 trial on the PTX-35 Cancer Drug.
2. 20 minute non invasive diagnostic Covid Test being developed.
Market Data 
Markets 
AI
